Newsroom 2026
Everything BrainStorm published in 2026.
Latest from BrainStorm
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) (“BrainStorm” or the “Company”), a developer of cell therapies for neurodegenerative diseases, today announced that members of its executive leadership team, including President and Chief Executive Officer Chaim Lebovits and Executive Chairman Peter J. Pitts, will participate in the 31st edition of the Dubai International Pharmaceuticals & Technologies Conference and Exhibition (DUPHAT), to be held August 25 to 27, 2026, at the Dubai World Trade Centre in Dubai, UAE.
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major strategic expansion of its executive leadership team.
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately.
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000.
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update.
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update.
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a second definitive agreement for an additional $1 million strategic private placement. This brings the total capital raised in Februa
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a definitive agreement for a strategic private placement of $1 million.
No press releases match that search. Try a shorter phrase, or clear the field to see the full list.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.